2018-2019 Psychiatric Pharmacotherapy Review Book

Author: Jolene Bostwick, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the, signs and symptoms, diagnostic criteria, and pathophysiology for anxiety and anxiety-related disorders.
2. Explain the use of common rating scales for research, diagnosis, and management of anxiety and anxiety-related disorders.
3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of anxiety and anxiety-related disorders.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in anxiety and anxiety-related disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for anxiety and anxiety-related disorders.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of anxiety and anxiety-related disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with anxiety and anxiety-related disorders.

Author: Carol Ott, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for bipolar disorder.
2. Explain the use of common rating scales for research, diagnosis, and management of bipolar disorder.
3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of bipolar disorder.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in bipolar disorder. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for bipolar disorder.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of bipolar disorder in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with bipolar disorder.

Author: Norman Carroll, BSPharm, MS, PhD
Learning Objectives
At the end of this program, the participant should be able to:

1. Explain the unique, core components of a pharmacoeconomic analysis.
2. Describe the differences between the four primary perspectives from which a pharmacoeconomic analysis can be conducted.
3. Contrast four economic evaluation methods commonly applied to pharmacy practice in today's healthcare settings, including the different outcomes that are employed by each method.
4. Describe an incremental cost-effectiveness ratio.
5. Distinguish between a systematic review and a meta-analysis.
6. Outline key features of a meta-analysis and how the data are analyzed.
7. Describe the essential features of humanistic outcome measures including health status, patient satisfaction, work outcomes, and patient-based assessments.
8. Compare and contrast decision trees and Markov modeling for pharmacoeconomic analysis.

Author: Sandra Mullen, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for neurodevelopmental, disruptive, impulse-control, conduct and genetic disorders.
2. Explain the use of common rating scales for research, diagnosis, and management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of neurodevelopmental, disruptive, impulse-control, and conduct disorders.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in neurodevelopmental, disruptive, impulse-control, and conduct disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for neurodevelopmental, disruptive, impulse-control, and conduct disorders.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of neurodevelopmental, disruptive, impulse-control, and conduct disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Recognize the behavioral phenotypes, major medical complications, risk factors, pathogenesis, clinical course, and drug therapy treatment options for patients with the following syndromes:
   • Down Syndrome
   • Prader-Willi Syndrome
   • Fragile X Syndrome
   • Klinefelter’s Syndrome
   • Rett’s Syndrome
10. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with neurodevelopmental, disruptive, impulse-control, and conduct disorders.

Author: Traci Turner, PharmD, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for personality disorders and eating disorders.
2. Explain the use of common rating scales for research, diagnosis, and management of personality disorders and eating disorders.
3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of personality disorders and eating disorders.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in personality disorders and eating disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for personality disorders and eating disorders.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of personality disorders and eating disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with personality disorders and eating disorders.

Author: Lisa W. Goldstone, MS, LPC, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for schizophrenia and movement disorders.
2. Explain the use of common rating scales for research, diagnosis, and management of schizophrenia and movement disorders.
3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of schizophrenia and movement disorders.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in schizophrenia and movement disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for schizophrenia and movement disorders.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of schizophrenia and movement disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with schizophrenia and movement disorders.

Author: Calleen Lavinghousez, PharmD, BCPS, BCPP
Learning Objectives
At the end of this program, the participant should be able to:

1. Describe the signs and symptoms, diagnostic criteria, and pathophysiology for substance use disorders.
2. Explain the use of common rating scales for research, diagnosis, and management of substance use disorders.
3. Discuss the efficacy of pharmacologic and nonpharmacologic treatment options (including natural products, if applicable) in the acute and long-term management of substance use disorders.
4. Outline the mechanisms of action, pharmacokinetic, pharmacodynamic, and pharmacogenetic properties (if applicable), adverse events, significant drug interactions, and warnings/precautions (including medical comorbidities, black box warnings, and REMS programs) for drugs used in substance use disorders. 
5. Describe treatment guidelines and landmark clinical trials, including study design, strengths and weaknesses, and implications for practice for substance use disorders.
6. Select an evidence-based drug therapy regimen (drug, dose, schedule, and duration of therapy) for stabilizing symptoms and preventing relapse given the clinical presentation of a specific patient.
7. Outline a plan for monitoring and managing the safety and efficacy of drug therapy.
8. Describe the management of substance use disorders in special populations (e.g., pregnancy/lactation, children, and elderly).
9. Identify essential information to discuss during patient education about drug therapy and organizations that advocate and provide resources for individuals with substance use disorders.